ALNOV Novacyt S.A.
0.4610EUR+2.44%Mkt Cap: 36.33M $P/E: —1d ago
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmenta…
Industry Peers
Medical Devices$174.36BUSDP/E 32.3
$112.53BUSDP/E 21.6
$109.40BUSDP/E 29.6
$61.45BUSDP/E 17.2
$50.23BUSDP/E 51.9
$46.06BUSDP/E 19.2
$32.79BUSDP/E 34.5
$29.90BUSDP/E 15.1
$23.37BUSDP/E 17.8
$22.58BUSDP/E 18.5
$20.58BUSDP/E 25.8
$17.06BUSDP/E 27.9
$17.47BUSDP/E 22.2
$12.73BUSD
$12.49BUSDP/E 77.9
$11.27BUSDP/E 18.3
$10.28BUSDP/E 19.6
$10.16BUSDP/E 48.1
$9.81BUSDP/E 27.8
$9.73BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
IIdeal Investisseur | ||
 Could Illumina’s Novacyt Collaboration Framework Quietly Reshape Its Clinical Sequencing Narrative (ILMN)? In September 2026, Novacyt S.A. announced it had entered into a five-year Master Collaboration Agreement with Illumina, creating a framework for separate project-based deals in product development and commercial collaboration. This structure gives Illumina a flexible way to tap Novacyt’s complementary expertise without committing upfront capital to specific programs, potentially broadening future genomic applications. We’ll now examine how this new Master Collaboration framework with... | ||